ReviewThe European journal of neuroscience2026
Glutamate Delta 1 Receptor in Synapses, Circuits, and Disease.
Review in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Calcitonin Gene-Related Peptide (CGRP)-Containing Terminals in the Central Amygdala of Mice and Monkeys: Ultrastructural Analysis and Subsynaptic Expression of GluD1.The European journal of neuroscience · 2026Article
- GluD1 is localized at cholinergic synapses and is an acetylcholine receptor.Molecular psychiatry · 2026Article
- Glutamate Delta 1 Receptor in Synapses, Circuits, and Disease.The European journal of neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The glutamate delta 1 receptor (GluD1) remained largely unexplored since its cloning three decades ago because it lacked typical ligand-gated ion channel activity. In the last decade, much progress has been made in identifying its potential function. This research has been greatly enhanced by the development of specific tools to determine receptor expression and distribution and genetic mouse models to explore region specific roles in regulating circuits and behavior. Major strides have also been taken in understanding the structure-function of the receptor. These studies demonstrate that GluD1 has many distinctive characteristics including synaptogenic activity at both excitatory and inhibitory synapses, the ability of the ligand-binding domain to bind not only D-serine but also GABA, its unique structural arrangement among the ionotropic glutamate receptor family in relation to domain swapping and the ability to induce tonic currents in the native system. Studies have also identified its role in regulating the postsynaptic content of AMPA and NMDA receptors and synaptic plasticity. Finally, human genetic studies revealed the relationship of GluD1 with neuropsychiatric disorders, including schizoaffective disorders and intellectual disability, which is consistent with the phenotypes observed in mice upon GluD1 ablation. The role of GluD1 is also becoming evident in neurological disorders, particularly chronic pain. Thus, GluD1 has quickly emerged as a receptor with multifaceted roles in physiology and pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.